enVVeno Medical Corporation NVNO
8.67
(0.42)
(4.62%)
as of 25 Sep
- Market cap
- $6.3M
- P/E
- 0.0×
Follow NVNO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 46.37 | 73.97 | 110.75 | 110.75 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | (5.34) | (9.56) | (19.75) | (19.75) |
P/B ratio |
— | — | — | — | — | — | 8.75 | 6.78 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | — | 22.69 | 10.08 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | — | 42.42 | 83.65 | 125.38 | 125.38 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (1.34) | (2.46) | (6.96) | (6.96) |
EV/FCF |
— | — | — | — | — | — | (1.27) | (2.45) | (7.17) | (7.17) |
Quick Ratio |
13.30 | 20.60 | 33.85 | 25.52 | 34.64 | 2.93 | 0.70 | 1.82 | 0.04 | 0.19 |
Current Ratio |
13.58 | 20.88 | 34.23 | 25.78 | 34.84 | 3.00 | 0.76 | 1.86 | 0.06 | 0.30 |
Net Debt/EBITDA |
1.38 | 1.85 | 1.88 | 1.54 | 3.22 | 1.04 | 0.10 | 2.37 | (0.47) | (0.03) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 3.37% | 2.97% | 2.41% | 16.54% | 0.00% | 93.63% | 10.54% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.04 | 0.57 | 0.00 | (0.19) | (0.04) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.21 | 0.39 |
Operating CF/Net income |
0.80 | 0.77 | 0.80 | 0.63 | 0.72 | 0.79 | 0.77 | 0.39 | 0.51 | 0.92 |
Capex/Depreciation |
(0.01) | (0.07) | (0.06) | (0.22) | (0.81) | (0.47) | (0.92) | 0.00 | 0.08 | 0.83 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (56.21%) | (49.39%) | (55.38%) | (52.98%) | (53.75%) | (240.92%) | (503.94%) | 359.63% | 107.51% | 48.60% | |
| (52.26%) | (46.63%) | (52.09%) | (49.66%) | (48.44%) | (139.46%) | (218.07%) | (566.40%) | (412.80%) | (186.62%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,433.53%) | (759.09%) | 0.00% | (1,914.23%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(72.78%) | (52.17%) | (51.25%) | (64.20%) | (30.56%) | (143.66%) | 7,034.50% | (1,220.17%) | 302.67% | 412.10% |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 62.59 | 30.44 | 88.15 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7,070.83% | 663.83% | 153.92% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15,742.31% | 3,474.28% | 1,292.58% | 589.74% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.50 | 0.69 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,019.23% | 1,030.28% | 208.10% | 192.16% |
Graham Net Nets |
— | — | — | — | — | — | (0.12) | 0.10 | (0.56) | (0.56) |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | 6,317.32 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (89.31%) | (122.99%) | (35.50%) | (35.50%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (72.27%) | (46.22%) | (15.79%) | (15.79%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.73 | 17.44 | 60.30 | 113.90 |
Operating CF per Share |
(26.43) | (34.36) | (53.79) | (48.79) | (47.89) | (208.62) | (327.58) | (594.00) | (600.31) | (495.25) |
Capex per Share |
(0.01) | (0.08) | (0.09) | (0.36) | (1.49) | (4.90) | (20.22) | (1.16) | 22.19 | 18.13 |
Free Cash Flow per Share |
(26.44) | (34.44) | (53.88) | (49.15) | (49.38) | (213.52) | (347.79) | (595.16) | (578.13) | (477.12) |
Cash per Share |
47.90 | 88.07 | 132.38 | 121.97 | 221.21 | 253.66 | 72.62 | 256.13 | 11.10 | 8.19 |
Shareholders Equity per Share |
46.06 | 86.04 | 131.77 | 120.99 | 219.90 | 192.88 | 54.99 | 190.32 | (1,590.07) | (611.51) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
46.06 | 86.04 | 131.77 | 120.99 | 219.90 | 192.88 | 54.99 | 190.32 | (1,590.07) | (611.51) |
Free Cash Flow |
(15.57) | (16.87) | (18.89) | (15.73) | (12.22) | (7.86) | (6.26) | (6.37) | (4.05) | (3.29) |
Working Capital |
26.70 | 41.64 | 45.55 | 37.91 | 53.46 | 6.38 | (0.45) | 1.31 | (2.75) | (0.93) |
Capital Expenditures |
0.00 | (0.04) | (0.03) | (0.11) | (0.37) | (0.18) | (0.36) | (0.01) | 0.16 | 0.13 |
Net Current Asset Value |
26.39 | 40.94 | 44.49 | 36.50 | 51.75 | 6.13 | (1.02) | 1.31 | (13.17) | (5.61) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.66 | 0.07 | (0.37) | (0.16) |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (24,440.38%) | (8,763.50%) | (1,954.84%) | (474.65%) |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
9.59 | 2.90 | 1.63 | 1.01 | 0.73 | 0.96 | 1.15 | 255.58 | 77.70 | 5.25 |
Cash ROIC |
(28.22%) | (19.95%) | (20.72%) | (20.39%) | (11.25%) | (48.40%) | (217.82%) | (133.60%) | 47.07% | 86.69% |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 5.55 | 3.75 | 6.99 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.59 | 0.46 | 0.29 | 0.00 | 0.00 | 0.42 | 0.81 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | 4.62 | 8.91 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 845.41 | 451.31 | 1,321.60 | 0.00 | 0.00 | 1,262.06 | 244.14 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | 79.05 | 40.95 |
Average Receivables |
— | — | — | — | — | — | — | 0.03 | 0.11 | 0.11 |
Average Payables |
1.73 | 1.38 | 1.12 | 0.89 | 0.98 | 1.31 | 1.15 | 1.26 | 1.00 | 1.00 |
Average Inventory |
— | — | — | — | — | — | — | — | 0.09 | 0.09 |
Average Assets |
37.26 | 46.79 | 45.15 | 49.68 | 34.12 | 6.99 | 3.50 | 2.89 | 2.00 | 2.00 |
Average Common Equity |
34.64 | 44.18 | 42.46 | 46.57 | 30.75 | 4.04 | 1.51 | (4.55) | (7.67) | (7.67) |
Columns are period end dates